Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-22T23:18:00.106Z Has data issue: false hasContentIssue false
  • English
  • Français

Etude comparative multicentrique en double aveugle de deux benzodiazépines chez 117 patients ambulatoires - alprazolam vs clobazam

Published online by Cambridge University Press:  28 April 2020

H. Hayoun ,
M.F. Hirigoyen ,
Y. Prigent  and
M. Brun
H. Hayoun
Affiliation:
Laboratoires Upjohn, Tour Franklin, Cédex 11, 92081, Paris La Défense
M.F. Hirigoyen
Affiliation:
45, rue de la Chaussée-d’Antin, 75009 Paris
Y. Prigent
Affiliation:
4, rue Amiral-Ronarc’h, 29000 Quimper
M. Brun
Affiliation:
64, rue Michel-Ange,, 75016 Paris
Get access

Résumé

L’alprazolam et le clobazam ont été comparés au cours d’une étude prospective randomisée en double aveugle d’une durée de quatre semaines, en stricte monothérapie à posologie ajustée en fonction de l’efficacité et de la tolérance du malade, chez 117 patients ambulatoires présentant un trouble névrotique anxieux selon les critères du DSM II, dont l’intensité était comprise entre 18 et 35 à l’échelle d’anxiété de Hamilton.

L’efficacité de l’alprazolam est significativement supérieure à celle du clobazam sur l’appréciation globale de l’efficacité selon le médecin (p = 0.04) et le malade (p = 0.03) sur l’un des symptômes-cibles (p = 0.02), sur la tolérance globale (p = 0.02), ainsi que sur le nombre d’effets secondaires (p = 0.05); il n’existe pas de différence significative entre les deux produits sur l’échelle de Hamilton ou sur la version abrégée à 24 items de l’échelle d’auto-évaluation B.A.T.E. (Bonis Anxiété Trait Etat). Les posologies journalières moyennes utilisées en fin d’essai ont été de 2.95 mg et 28.5 mg pour l’alprazolam et le clobazam respectivement.

Les résultats observés concernant l’efficacité et la tolérance des deux produits sont discutés en termes de comparabilité des groupes, de sous-catégories d’anxiété étudiées, de posologies utilisées, ainsi que des nuances observées selon qu’on raisonne en termes d’évaluation globale ou en termes d’échelles psychométriques.

Summary

Summary

A prospective randomized, double-blind trial has been conducted comparing alprazolam and clobazam administered in strict monotherapy for four weeks, using flexible dosage adjusted according to efficacy and side effects in 117 anxious outpatients.

To be included in the study, patients had to be aged from 18 to 65, present primary anxiety with anxiety symptoms present for a minimum of one month, have a total score of between 18 and 35 on the Hamilton Anxiety Rating Scale (HARS), and be free of any previous psychotropic medication for at least four days.

Although no significant difference was observed regarding the HARS or the abbreviated 24-item version of the B.A.T.E. (Bonis Anxiété Trait Etat) self rating scale (Appendix 1), the efficacy of alprazolam was judged significantly superior to that of clobazam regarding psychiatrists’ (p = .04) and patients’ (p = .02) average score for efficacy, one target symptom (p = .02), global evaluation of safety (p = .02) and number of side effects (p =.05) (see Tables 3, 6 and 7).

However, both groups did show dramatic improvement from baseline for the majority of efficacy measures. For example, on the HARS score, the alprazolam group went from a mean of 25.6 at the initial visit to a mean score of 9.7 at Week 4, while the clobazam group went from 25.6 to 11.0. At the end of the trial, mean dosage reached 2.95 mg for alprazolam (dose range 1.5 - 4.5 mg) and 28.5 mg for clobazam (dose range 10 - 40 mg) (see Table 9).

The most common side effects reported during the study were drowsiness, dizziness, and dry mouth in both groups, see Table 6.

In conclusion, both alprazolam and clobazam appeared to be effective in alleviating the symptoms of anxiety. However, significant differences between the two groups appeared in favour of alprazolam as regards a number of measures of efficacy and safety.

Such results need to be confirmed by currently used psychometric scales before being widely accepted.

Keywords

AlprazolamClobazamAnxiétéEtude en double aveugleAlprazolamClobazamAnxietyDouble-blind study
Type
Research Article
Information
Psychiatry and Psychobiology , Volume 2 , Issue 3 , 1987 , pp. 202 - 213
Copyright
Copyright © European Psychiatric Association 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aden, G.C. - Alprazolam in clinically anxious patients with depressed mood. J Clin Psychiatry 1983; 44: 22-24.Google ScholarPubMed
Aden, G.C., Theip, S.G. - Alprasolam compared to diazepam and placebo in the treatment of anxiety. J Clin Psychiatry 1980; 41: 245-248.Google Scholar
Arnau, C., Costa Molinari, J.M., Pina, C., Vallve, C. - Clobazam: single or divided doses? EurJ Clin Pharmacol 1982; 22: 235-238.CrossRefGoogle ScholarPubMed
Borland, R.G., N1cholson A.N. - Immediate effects on human performance of a 1,5-benzodiazepine (clobazam) compared to the 1,4-benzodiazepines, chlordiazepoxide hydrochloride and diazepam. Br J Clin Psychiatry 1974; 2: 215-221.Google Scholar
Botte, L., Bienfait, J., Dethier, J.et al. - Comparaison clinique entre alprazolam et lorazepam. Acta Psychiatr Belg 1981; 81: 596-608.Google Scholar
Botter, P.A. - Single daily dose treatment of anxiety with clobazam. Cuir Med Res Opin 1980; 6: 593-597.CrossRefGoogle ScholarPubMed
Brogden, R.N., Heel, R.C., Speight, R.M., Avery, G.S. - Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. Drugs 1980; 20: 161-178.CrossRefGoogle ScholarPubMed
Caetano, D., Knobel, M., Soares, C.A. et al. - doubleblind study comparing the efficacy of alprazolam with bromazepam in anxious outpatients. Jomal Brasileiro de Psiquiatria 1984; 33(2): 145-147.Google Scholar
Cofin, J.B. - Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients. J Clin Psychiatry 1981; 42: 347-351.Google Scholar
Davison, K., Earquharson, R.G., Khan, M.C., Majid, A. - A double-blind comparison of alprazolam, diazepam and placebo in the treatment of anxious outpatients. Psychopharmacology 1983; 80: 308-310.CrossRefGoogle Scholar
De Bonis, M. - Etude de l’anxiete par la methode des questionnaires. II. Travaux experimentaux. Rev Psychol Appl 1973; 23: 105-131.Google Scholar
Doongaji, D.R., Sheth, A.S., Apte, J.S. et al - A comparative study of single and multidoses of clobazam vs diazepam in anxiety neurosis. Cuir TherRes 1985; 37: 3: 398-405.Google Scholar
Feighner, J.P. - Open label study of alprazolam in severely depressed inpatients. J Clin Psychiatry 1983; 44: 322-334.Google ScholarPubMed
Greenblatt, D.J., Shader, R.I. - Benzodiazépines in clinical practice. Raven Press, New-York, 1974.Google Scholar
Greiss, K.C., Fogari, R. - Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety. J Clin Pharmacol 1980; 20: 693-699.CrossRefGoogle ScholarPubMed
Hecquet, S., Puech, A.J., Lecrubier, Y. - Etude controlee en double aveugle comparant l’alprazolam au lorazepam chez des sujets anxieux ambulatoires. Thérapie 1984; 30: 253-261.Google Scholar
Hester, J.B., Vonvoigtlander, P.F. - 6-Aryl-4H-striazolo (4, 3-a) (1,4) benzodiazepines. Influence of 1-substitution on pharmacological activity. J Med Chem 1979; 22: 1390-1398.CrossRefGoogle Scholar
Hindmarch, I., Parrott, A.C. - The effects of repeated nocturnal doses of clobazam, dipotassium chlorazepate and placebo on subjective ratings of sleep and early morning behaviour and objective measures of arousal, psychomotor performance and anxiety. Br J Clin Pharmacol 1979; 8: 325-329.CrossRefGoogle ScholarPubMed
Lahti, R.A., Barsuhn, C. - The effect of minor tranquilizers on stress-induced increases in rat plasma corticosteroids. Psychopharmacology 1974; 35: 215-222.CrossRefGoogle ScholarPubMed
Lahti, R.A., Sethy, V.H., Barsuhn, C., Hester, J.B. - Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 1983; 22: 1277-1282.CrossRefGoogle ScholarPubMed
Maletzky, B.M. - Anxiolytic efficacy of alprazolam compared to diazepam and placebo. J Int Med Res 1980; 8: 139-143.CrossRefGoogle ScholarPubMed
Nakajima, R., Hattori, C., Nagawa, Y. - Structureactivity relationship of s-s-triazolo-1, 4-benzodiazepine in central nervous System depressant action. Jpn J Pharmacol 1971; 21: 489-495.CrossRefGoogle Scholar
Nakajima, R., Take, Y., Moriya, R, Saji, Y., Yui, T., Nagawa, Y. - Pharmacological studies on new potent central depressants, 8-chloro-6-phenyl-4H-s-triazolo- (4, 3-a) (1, 4) benzodiazepine (D-40TA) and its 1-methyl-analogue (D-6SMT). 3 pn3 Pharmacol 1971; 21: 497-514.Google Scholar
Norman, T.R., Burrows, G.D. - Plasma concentrations of benzodiazepines - A review of clinical findings and implications. Prog Néuropharmacol Biol Psychiatry 1984; 8: 115-126.CrossRefGoogle ScholarPubMed
Parrot, A.C., Hindmarch, L, Stonier, P.D. - Nomifensine, clobazam and HOE 8476: Effects on aspects of psychomotor performance and cognitive ability. Eur3 Clin Pharmacol 1982; 23: 309-313.CrossRefGoogle Scholar
Puech, A.J. - Pour une utilisation plus rationnelle des benzodiazepines. Entretiens de Bichat, 27 sept. 1984.Google Scholar
Puech, A.J., Hecquet, S., Lecrubier, Y. et al. - Comparaison chez l’homme des effets anxiolytiques de deux benzodiazepines (alprazolam et diazepam): problemes methodologiques. Thérapie 1984; 39: 65-98.Google Scholar
Rickels, K., Feighner, J., Smith, W.T. - Alprazolam, amitriptyline, doxepin and placebo in the treatment of depression. Arch Gen Psychiatry 1985; 42: 134-141.CrossRefGoogle ScholarPubMed
Ropert, R., Bernes, J., Dachary, J.M. - Etude en double aveugle comparant l’efficacite et la tolerance de l’alprazolam et du bromazepam a doses ajustables chez 119 sujets anxieux ambultoires. Encéphale 1987; XIII: 89-95.Google Scholar
Ropert, R., Cottin, M. - Etude controlee en double aveugle comparant l’alprazolam au clorazepate dipotassique chez des sujets anxieux ambulatoires. Psychologie Médicale 1984; 16,9: 1595-1605.Google Scholar
Ropert, R., Cottin, M. - Etude controlee en double aveugle comparant l’alprazolam au clorazepate dipotassique chez des sujets anxieux ambulatoires. Psychologie Médicale 1984; 16.9: 1595-1605.Google Scholar
Rosental, W., Mikus, P. - Anxiety treatment with outpatients. Efficiency and tolerance of alprazolam and bromazepam. MMW1984; 126: 1126-1128.Google Scholar
Rudzik, A.D., Hester, J.B., Tang, A.H., Straw, R.N., Friis, W. - Triazolobenzodiazepines, a new class of central nervous System depressant compounds. In: The benzodiazépines, 285-298, Raven Press, New York, 1973.Google Scholar
Sethy, V.H., Hodges, D.H. - Alprazolam in a biochemical model of depression. Biochem Pharmacol 1982; 19: 3155-3157.CrossRefGoogle Scholar
Sethy, V.H., Hodges, D.H. - Antidepressant activity of alprazolam in a reserpine-induced model of depression. Drug Dev Res 1985; 5: 179-184.CrossRefGoogle Scholar
Sheehan, D.V. - Current perspectives in the treatment of panic and phobie disorders. Drug Ther-J Clin Ther 1982; 12: 179-193.Google Scholar
Sheehan, D.V., Coleman, J.H., Greenblatt, D.J. et al. - Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 1984; 4: 66-75.CrossRefGoogle ScholarPubMed
Steiner-Chastel, N., Lader M.H. - Effects of single doses of clobazam and diazepam on psychological functions in formai subjects. R Soc Med Int Symp Sériés 1981 ; 43: 23-32.Google Scholar
Torres Ruiz, A. - A double-blind study of alprazolam and lorazepam in the treatment of anxiety. J Clin Psychiatry 1983; 44: 2.Google Scholar
Wallis, T.D., Valle-Jones, J.C., Craven, J.R., Hanks, G.W., Stonier, P.D. - Single daily dose treatment of anxiety with clobazam or dipotassium clorazepate. Br J Clin Pharmacol 1979; 7: 123S-127S.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.